正在加载公司
Keep exploring
The themes Novo Nordisk A/S is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The themes it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And CompanyUS$1.36TA+
JNJJohnson & JohnsonUS$688.6BA+
MRKMerck & Co., Inc.US$364.3BA
NVSNovartis AGUS$306.3BA
AMGNAmgen Inc.US$251.9BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A
怎么赚钱
- Sales of prescription medicines for diabetes, obesity and other conditions
竞争对手
卖什么3
Wegovy injection
An injectable semaglutide medicine used for weight management.
Wegovy pill
A once-daily semaglutide pill used for weight management.
Ozempic
An injectable semaglutide medicine for type 2 diabetes.
谁在买3
- People with diabetes or obesity who obtain medicines through a prescription or buy them directly in self-pay channels.
- Pharmacies and telehealth providers that supply medicines to patients.
- Private insurers and public programs that cover prescription medicines, including Medicare Part D in the United States.
靠什么支撑，什么会击垮它
业务依赖什么
- 1Recent sales growth and product launches rely on glucagon-like peptide-1 (GLP-1) medicines, including semaglutide brands such as Wegovy and Ozempic.
- 2Access to obesity medicines in the United States depends on insurance coverage and what patients can afford to pay themselves; the company said most Wegovy pill prescriptions there were self-pay in Q2 2026.
- 3Commercial supply depends on manufacturing capacity; the company said its new active pharmaceutical ingredient facilities were contributing very little commercial supply in Q2 2026.
可能出什么问题
- 1Competition and lower realized prices can reduce sales from obesity and diabetes medicines; the company cited intensifying United States competition and pricing pressure in Q2 2026.
- 2Generic versions of semaglutide can reduce sales where patent protection expires; the company reported early generic entries in some international markets.
- 3Cybersecurity breaches could disrupt the business.
关于Novo Nordisk A/S
Novo Nordisk makes medicines for diabetes and obesity, including Wegovy for weight management and Ozempic for type 2 diabetes. Its medicines reach patients through healthcare providers and pharmacies, with payment coming from insurers and public health programs or directly from patients. It also develops medicines for other conditions, including rare diseases.
- 总部
- Bagsværd, Denmark
- 成立于
- 1923
- 员工人数
- around 66,700 (Q2 2026, medium)
- 上市于
- New York Stock Exchange
- 财年结束
- December 31
基于 Novo Nordisk A/S 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 该公司以 DKK 申报。数字按当前汇率 US$1.00 = 6.7640 DKK 换算为美元，并对所有期间一视同仁——因此增长和利润率属于公司本身，而不是汇率。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
